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Meera Bose,a,b Eric Sanders-Buell,a,b Robert Paris,d Merlin L. Robb,a,b Deborah L. Birx,b* Mark S. De Souza,a,d
Francine E. McCutchan,a,b* Nelson L. Michael,b Jerome H. Kimb
U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USAa; U.S. Military HIV Research Program,
Walter Reed Army Institute of Research, Silver Spring, Maryland, USAb; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailandc; Armed Forces
Research Institute of Medical Sciences, Bangkok, Thailandd
The RV144 HIV-1 vaccine trial (Thailand, 2003 to 2009), using immunogens genetically matched to the regional epidemic, dem-
onstrated the first evidence of efficacy for an HIV-1 vaccine. Here we studied the molecular evolution of the HIV-1 epidemic
from the time of immunogen selection to the execution of the efficacy trial. We studied HIV-1 genetic diversity among 390 vol-
unteers who were deferred from enrollment in RV144 due to preexisting HIV-1 infection using a multiregion hybridization as-
say, full-genome sequencing, and phylogenetic analyses. The subtype distribution was 91.7% CRF01_AE, 3.5% subtype B, 4.3%
B/CRF01_AE recombinants, and 0.5% dual infections. CRF01_AE strains were 31%more diverse than the ones from the 1990s
Thai epidemic. Sixty-nine percent of subtype B strains clustered with the cosmopolitanWestern B strains. Ninety-three percent
of B/CRF01_AE recombinants were unique; recombination breakpoint analysis showed that these strains were highly embedded
within the larger network that integrates recombinants from East/Southeast Asia. Compared to Thai sequences from the early
1990s, the distance to the RV144 immunogens increased 52% to 68% for CRF01_AE Env immunogens and 12% to 29% for sub-
type B immunogens. Forty-three percent to 48% of CRF01_AE sequences differed from the sequence of the vaccine insert in Env
variable region 2 positions 169 and 181, which were implicated in vaccine sieve effects in RV144. In conclusion, compared to the
molecular picture at the early stages of vaccine development, our results show an overall increase in the genetic complexity of
viruses in the Thai epidemic and in the distance to vaccine immunogens, which should be considered at the time of the analysis
of the trial results.
Amajor obstacle for the development of a safe and globallyeffective HIV vaccine is the extensive genetic diversity of the
virus (1, 2). Most infections in the pandemic are due to HIV type
1 (HIV-1) groupM, which is classified into nine subtypes (A to D,
F to H, J, and K) differing by roughly 15% in their full-genome
nucleotide sequence and up to 35% in the sequences of the gp120
envelope protein. Numerous recombinants have been character-
ized in the pandemic (3). Some of them have achieved wide dis-
semination (i.e., circulating recombinant forms [CRFs]), while
others have been retrieved from only a single individual (i.e., unique
recombinant forms [URFs]). HIV-1 subtypes and recombinants
have distinct geographic distributions (4); for example, subtype B is
thepredominant strain inNorthAmericaandWesternEurope,while
infections in South, East, and Southeast Asia are mostly due to sub-
types B, C, and CRF01_AE and their recombinants.
Due to the early and continuous participation in the planning
and execution of HIV-1 vaccine trials, the Thai epidemic is one of
the best studied (5). The early 1990s saw a great expansion of the
HIV-1 epidemic, with a nationwide seroprevalence among young
military conscripts of 3.7%, reaching 12% among those from
northern Thailand (6, 7). At that time, HIV-1 strains segregated
on the basis of risk factors, with subtype B predominating among
injecting drug users (IDUs) and CRF01_AE being the main clade
among those with heterosexual exposure risk (8–12), though
through ensuing years, CRF01_AE has come to predominate the
epidemic among IDUs as well (13–21).
From the mid-1990s to the mid-2000s, a series of molecular
processes (e.g., the expansion of the genetic diversity within cir-
culating subtypes, shifts in the proportions of different molecular
forms, the emergence of intersubtype recombinants, and the in-
flux of new strains fromother epidemics) playedmajor roles in the
evolution of this epidemic. First, it was noted that the within-
subtype interhost genetic divergence had increased significantly
compared to that noted in earlier surveys (9, 10, 17, 22–25). Sec-
ond, the barriers that maintained the segregation of subtypes on
the basis of risk factors started to efface; the representation of
CRF01_AE among IDUs increased, especially among new infec-
tions (26), to the point where CRF01_AE accounted for 80 to 90%
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of the cases in Bangkok and the northern province of Chiang Mai
(27, 28). Coinfections (29) and superinfections (30) with subtype
B and CRF01_AE were documented, and intersubtype recombi-
nantswere detected among individuals with either IDU (28, 31) or
heterosexual (32, 33) exposure. While most of the recombinants
were URFs, a new CRF, CRF15_01B, was found throughout the
country among individuals with either risk factor, reinforcing the
linkage between the different epidemics in Thailand (31, 32). Fi-
nally, the connection of the Thai HIV-1 epidemic with other epi-
demics in the region, through travel and trafficking of drugs and
persons, has been reflected in the genetic relatedness of Thai
strains to those from other countries in the Golden Triangle (i.e.,
a major illicit opium-producing area spanning Myanmar
[Burma], Vietnam, Laos, and Thailand) (34, 35) and China (36).
Subtypes A, C, D, and CRF02_AG—which are more common in
African epidemics—have been detected sporadically (37–39);
however, to date there have been no indications that these strains
have spread locally.
In preparation for the RV144 trial, community cohort surveys
were conducted from 1998 to 2001 in Rayong and Chon Buri
Provinces (i.e., the areas where the trial was later to be executed)
and found that 90.5% of prevalent infections were due to
CRF01_AE, 2.4% were due to subtype B, and 7.2% were due to
recombinants (including CRF15_01B) or dual infections (40).
Prospective volunteers for RV144 were enrolled in screening pro-
tocol RV148 to assess eligibility (41); those with preexisting HIV
infection were deferred from enrollment in the RV144 trial and
are the subject of the current study. This study attempts (i) to
provide a molecular snapshot of the HIV-1 epidemic in eastern
Thailand between 2003 and 2005, (ii) to correlate the viral genetic
information in this cohort with the epidemiological characteris-
tics of the volunteers for RV144, and (iii) to determine the genetic
relationship between the immunogens incorporated in the vac-
cine and the viral strains that challenged the trial participants. The
HIV-1 strains characterized in RV148 were drawn at the same
time, from the same location, and from the same social networks
as those in the RV144 trial, and they represent one of the closest
descriptionswemay have to theHIV-1 strains towhich the RV144
participants might have been exposed during the trial. This study
is complementary to the recent work of Rolland et al. (42) that
describes a variable region 2 (V2)-delimited sieve analysis of
HIV-1 strains infecting RV144 trial participants, as it describes
viral strains that are the nearest possible approximations to the
viral strains to which the placebo and vaccine recipients in RV144
might have been exposed. The thorough analysis of near-full-
length RV144 breakthrough viruses is the focus of a separate re-
port (M. Rolland, unpublished data).
MATERIALS AND METHODS
Population under study. From September 2003 to December 2005,
26,676 volunteers in Rayong and Chon Buri Provinces in East Thailand
who consented for the RV144 trial were assessed for eligibility in the
setting of the screening protocol RV148. One hundred twenty-eight indi-
viduals were not referred for protocol-defined HIV testing because they
met at least one exclusion criterion and/or failed to meet at least one
inclusion criterion. Out of the 26,548 volunteers whowere tested forHIV,
418 had HIV infection (see reference 41 for details on the testing reagents
and algorithms), were counseled and referred to designated Ministry of
Public Health (MOPH) hospitals for evaluation of the status of their in-
fection, and were considered for standard treatment and care on the basis
of the publishedThaiMOPHguidelines (43; see reference 41 for details on
counseling). Samples from 390/418 individuals were available for HIV-1
genotyping. CD4T cell enumerationwas performedusing standard flow
cytometry (FACSCalibur; Becton, Dickinson, Palo Alto, CA), and HIV-1
RNAquantificationwas performedusing reverse transcription-PCR tech-
nology (Roche Amplicor version 1.5 test; Roche Diagnostics, Indianapo-
lis, IN).
Ethical review. The screening protocol RV148 was reviewed and ap-
proved by the ethical committees of the Thai MOPH, the Royal Thai
Army, Mahidol University, and the Human Subjects Research Review
Board of the U.S. Army Medical Research and Materiel Command. The
study was conducted in accordance with U.S. and Thai FDA regulations as
well as the International Conference on Harmonisation (ICH) technical re-
quirements for registration of pharmaceuticals for human use guideline on
good clinical practice (GCP) for clinical trials, guideline E6 (http://www.ich
.org/products/guidelines/efficacy/article/efficacy-guidelines.html).
HIV-1 genotyping. Viral RNA was extracted from serum samples by
robotic extraction (MagnaPure; Roche Diagnostics), and the determina-
tion of HIV-1 subtype and recombinants was achieved through a multi-
region hybridization assay (MHAbce) of the whole available sample set
and near-full-genome amplification and sequencing of a subset of sam-
ples.
(i) MHAbce version 2. The presence of infections with subtypes B, C,
and CRF01_AE, and recombinants and dual infections combining these
strains was evaluated using MHAbce version 2, as previously published
(32). Briefly, 8 regions throughout the HIV-1 genome (p17 in gag; pro-
tease, reverse transcriptase, and integrase in pol; the first exon of tat; gp120
and gp41 in env; and nef) were reverse transcribed andPCR amplifiedwith
universal primers. Subsequently, each region was subject to real-time
PCRs with respective fluorescent TaqMan probes specific for subtypes B,
C, and CRF01_AE. Samples with concordant patterns of probe reactivity
throughout the genome were assigned to the corresponding subtype or
CRF, while those samples showing discordant patterns of probe reactivity
were considered intersubtype recombinants. Patients with samples exhib-
iting dual-probe reactivity in the same genome region were considered
dually infected after verification by cloning and real-time PCR subtyping
of at least 20 clones per sample. Using typeability criteria determined at
assay validation, only samples showing probe reactivity in 4 or more ge-
nome regions were considered typed (32).
(ii) Near-full-genome amplification and sequencing. Near-full-ge-
nomeHIV-1 sequenceswere obtained as either a completeHIV-1 genome
or two half genomes overlapping by 1.5 kb, as previously described (44).
Phylogenetic analyses. Alignments of RV148 near-full-genome
HIV-1 sequences and subtype and CRF reference sequences (3) were ob-
tained using the HIVAlign program (http://www.hiv.lanl.gov/content
/sequence/VIRALIGN/viralign.html) and were manually edited with
BioEdit version 7.0.9.0 software (45). RV148 sequences were assigned to
the corresponding subtype or CRF through phylogenetic analyses of nu-
cleotide sequences conducted in the MEGA5 program (46) using maxi-
mum likelihood trees; bootstrap values supporting relevant clusters were
computed through the Kimura 2-parameter model (47) and neighbor-
joining trees (48) with 1,000 iterations. The structure of recombinant
forms was determined using the jumping profile hidden Markov model
(jpHMM; http://jphmm.gobics.de/) (49) and was confirmed through
subgenomic phylogenetic analysis. The location of all the recombination
breakpoints is reported in the HXB2 coordinate system.
Nucleotide sequence diversity was determined through a maximum
likelihood estimation using the general reversible model, as implemented
inHypothesis Testing Using Phylogenies (HyPhy) (50). The distance of the
deduced protein sequences of RV148 immunogens and published se-
quences from East and Southeast Asia to RV144 immunogens was com-
puted using the p-distance, Poisson (51), Jones-Taylor-Thornton (JTT)
(52), Dayhoff (53), and HIV-Between (54) models implemented in
MEGA5 and HyPhy. None of these models was specifically tailored to
weigh the impact of amino acid substitution on immune recognition. For
the current analysis, we selected the p-distance model, which is the one
Kijak et al.
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that makes the fewest a priori assumptions, as we found that it had a very
strong linear correlation with the more complex models (range of r2 val-
ues, 0.9557 to 0.9999) (data not shown).
Network analysis. The sharing of common recombination break-
points between RV148 intersubtype recombinants and published HIV-1
strains from East and Southeast Asia was studied using the RecDraw pro-
gram (55), allowing 27 bp of mapping imprecision (i.e., the average dis-
tance between the jpHMM-predicted and previously published break-
points, as determined by Schultz et al. [49]). Network diagrams were built
using the UCINET version 6.275/NetDraw version 2.091 (Analytic Tech-
nologies, Lexington, KY) and NodeXL (Social Media Research Founda-
tion; http://www.smrfoundation.org) programs.
Statistics. Differences in the distribution of gender, HIV-1 subtypes,
recombinants, and dual infections across sociodemographic characteris-
tics were assessed using the chi-square test and Fisher’s exact test (if the
expected cell count was less than 5) for categorical variables and through
the Wilcoxon rank sum test for continuous variables; crude odds ratios
and 95% confidence intervals (CIs) were calculated using JMP version
10.0 (SAS Institute, Cary, NC). JMP was also employed to assess differ-
ences in genetic diversity among time intervals and country of sampling
using the Wilcoxon rank sum test and to assess the linear fit between
genetic distances, computed by least-squares regression using different
models. All of the presented P values are unadjusted formultiple compar-
isons.
Nucleotide sequence accession numbers. The HIV-1 sequences ob-
tained in this study have been deposited in GenBank under accession
numbers JN248316 to JN248357.
RESULTS
Sociodemographic characteristics of the population under
study. In order to determine eligibility for enrollment in RV144,
volunteers were first enrolled in the screening protocol RV148.
Out of 26,548 volunteers whowere tested forHIV, 418 individuals
(1.57%) had a confirmed HIV infection and were deferred from
enrollment in RV144 (see Materials and Methods) (56). The so-
ciodemographic risk factors for HIV seropositivity have been pre-
viously reported (41) and included female sex, older age, lower
education, widowed/divorced/separated marital status, and fish-
erman/sex worker/entertainment worker self-reported occupa-
tion.
Samples from 390/418 volunteers who were ineligible for
RV144 because HIV infection was detected during screening were
available for HIV-1 genotyping. Table 1 shows their sociodemo-
graphic and clinical characteristics. Among the seropositive volun-
teers, comparable numbers of female (n 192) andmale (n 198)
individuals were represented. Statistically significant differences in
sociodemographic characteristics between male and female volun-
teers were observed. Male seropositive volunteers were enriched for
transgender individuals (P0.001), volunteerswhowere single (P
0.001), volunteers who had completed at least senior high school
(P0.02), or volunteerswhowereoffice/factoryworkers (P0.02).
Among females there was enrichment in volunteers who had not
completed primary school (P  0.03) or who were married (P 
0.001), divorced (P 0.001), entertainment workers (P 0.04), or
housewives (P0.001) (datanot shown).Thedistributionofplasma
viral load (pVL) and CD4 cell counts did not differ significantly be-
tweenmales and females (data not shown).
HIV-1 subtype distribution amongRV148 seropositive indi-
viduals.Out of the 390 specimens tested withMHAbce, 375 sam-
ples (96.2%) showed probe reactivity in 4 or more regions, which
was the preestablished typeability requirement (32) (seeMaterials
and Methods). The main reason for untypeability was undetect-
able pVL (data not shown). Results fromMHAbce showed a pre-
dominance of infections due to CRF01_AE (90.2%), followed by
B/CRF01_AE recombinants (6.1%) and subtype B (3.2%) (Table
2). Two cases showed dual-probe reactivity for subtype B and
CRF01_AE. Additionally, among the untyped samples, there was
one specimen showing probe reactivity with subtype C probes in
two regions and with CRF01_AE probes in one region. A near-
TABLE 1 Sociodemographic and clinical characteristics of screened
volunteers who were deferred from enrollment in the RV144 vaccine
trial due to preexisting HIV infection
Characteristic
Female (n
192) Male (n 198)
Total (n
390)
No. (%) of volunteers by gender
Female 192 (100) 10 (5.1) 202 (51.8)
Male 0 (0) 187 (94.4) 187 (48.0)
Missing 0 (0) 1 (0.5) 1 (0.2)
Age (yr)
Median 25 26 26
Interquartile interval 22–28 23–27 22–28
No. (%) of volunteers by the following
characteristic:
Birthplace
Chon Buri 44 (22.9) 52 (26.3) 96 (24.6)
Rayong 45 (23.4) 44 (22.2) 89 (22.8)
Other 103 (53.7) 102 (51.5) 205 (52.6)
Screening site
Chon Buri
Panthong 8 (4.2) 16 (8.1) 24 (6.2)
Sri Racha 11 (5.7) 17 (8.6) 28 (7.2)
Bang Lamung 48 (25.0) 54 (27.3) 102 (26.1)
Sattahip 30 (15.6) 23 (11.6) 53 (13.6)
Rayong
Ban Chang 12 (6.3) 20 (10.1) 32 (8.2)
Mueang 23 (12.0) 29 (14.6) 52 (13.3)
Ban Khai 23 (12.0) 19 (9.6) 42 (10.8)
Klaeng 37 (19.2) 20 (10.1) 57 (14.6)
Marital status
Single 21 (10.9) 97 (49.0) 118 (30.2)
Married 123 (64.2) 89 (44.9) 212 (54.4)
Separated 2 (1.0) 0 (0.0) 2 (0.5)
Divorced 40 (20.8) 11 (5.6) 51 (13.1)
Widowed 6 (3.1) 1 (0.5) 7 (1.8)
Education
Did not complete primary school 13 (6.8) 4 (2.0) 17 (4.3)
Primary school 107 (55.8) 99 (50.0) 206 (52.9)
Junior high school 54 (28.1) 60 (30.3) 114 (29.2)
Senior high school/vocational school 15 (7.8) 28 (14.1) 43 (11.0)
Vocation school 2 (1.0) 5 (2.5) 7 (1.8)
Bachelor’s degree or higher 1 (0.5) 2 (1.0) 3 (0.8)
Occupation
Laborer 56 (29.1) 62 (31.3) 118 (30.2)
Office/factory 35 (18.2) 57 (28.8) 92 (23.6)
Merchant/business 15 (7.8) 17 (8.6) 32 (8.2)
Housewife 26 (13.5) 0 (0.0) 26 (6.7)
Entertainment 15 (7.8) 6 (3.0) 21 (5.4)
Agriculture 8 (4.2) 10 (5.1) 18 (4.6)
CSW 8 (4.1) 9 (4.5) 17 (4.4)
Fishery 3 (1.6) 5 (2.5) 8 (2.0)
Government officer 1 (0.5) 4 (2.0) 5 (1.3)
Military/police 0 (0) 4 (2.0) 4 (1.0)
Student 0 (0) 3 (1.5) 3 (0.8)
Other 0 (0) 2 (1.0) 2 (0.5)
Unemployed 25 (13.0) 19 (9.6) 44 (11.3)
Plasma viral load (no. of RNA copies/ml)
Median 30,371 33,841.5 32,919
Interquartile interval 7,137–121,999 14,518.8–127,640 9,629–124,361
No. (%) of patients with VLs of400
copies/ml
8 (4.1) 6 (3.0) 14 (3.6)
CD4 cell count (no. of cells/l)
Median 401 397.5 399
Interquartile interval 260–568.75 276.75–583.25 272–577.5
No. (%) of patients with CD4 counts of:
200 cells/l 33 (17.1) 27 (13.6) 60 (15.3)
350 cells/l 73 (37.8) 77 (38.9) 150 (38.4)
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full-genome sequence was retrieved, revealing that the sample
corresponded to subtype C, clustering within the African radia-
tion (data not shown).
All typeable samples showing reactivity with subtype B probes
in at least one regionwere subject to near-full-genome sequencing
(Fig. 1). All 12 samples identified as pure subtype B by MHAbce
showed a concordant subtype designation by near-full-genome
sequencing. Out of the 23 samples identified as B/CRF01_AE re-
combinants by MHAbce, 16 were confirmed to be recombinants
by sequencing, while 1 and 6 strains were determined by near-full-
genome sequencing to be pure subtype B and CRF01_AE strains,
respectively. Detailed inspection of near-full-genome sequences
revealed that the main reason for heterotypic probe reactivity in
MHAbce was the presence of infrequent polymorphisms in the
probe binding sites, which had not been anticipated in the design
of the assay (32).
The subtype distribution combining MHAbce- and near-full-
genome sequencing-based genotyping is shown in Table 2. Over-
all, CRF01_AE strains accounted for 91.7% of the infections, and
pure subtype B strains were only slightly outnumbered by
TABLE 2 HIV clade distribution among 375 volunteers deferred from
enrollment in the RV144 vaccine trial due to preexisting HIV infection,
genotyped by MHAbce and full-genome sequencing
Clade
No. (%) of volunteers
MHAbce only
MHAbce with sequencing
confirmation
CRF01_AE 338 (90.2) 344 (91.7)
Subtype B 12 (3.2) 13 (3.5)
B/CRF01_AE recombinants 23 (6.1) 16 (4.3)
B/CRF01_AE dual infection 2 (0.5) 2 (0.5)
FIG 1 MHAbce reactivity pattern and genomic structure of typed samples showing reactivity with subtype B probes in one or more regions. Color-coded
horizontal bars represent the genomic structure based on near-full-genome sequencing, and the circles depict the corresponding MHAbce probe reactivity.
Vertical dotted lines indicate the genomic locations of theMHAbce probes. For sample 05TH640507, only a subgenomic sequence was retrieved (HXB2 residues
6991 to 7573). LTR, long terminal repeat.
Kijak et al.
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B/CRF01_AE intersubtype recombinants (3.5%and 4.3%, respec-
tively). While B/CRF01_AE dual infections were detected, they
were very infrequent (0.5%).
Analysis of near-full-genome sequences. (i) Subtype B. Se-
quences from the 13 subtype B sampleswere analyzed (Fig. 2). The
subtype B strains circulating in Southeast Asia can be subclassified
into two different clades on the basis of their genetic sequences
and especially their motif at the crown of the V3 loop in gp120:
sequences clustering with strains from the Americas andWestern
Europe carrying the GPGR motif in V3 (which are designated
WesternB throughout the text) and a separate cluster of sequences
identified primarily in Southeast Asia and China and carrying the
GPGQmotif in V3, referred to in the literature as B= or Thai B (57,
58). In RV148, 9 sequences clustered with strains from the West-
ern B radiation, while the remaining 4 sequences clustered within
the B= radiation (Fig. 2a). There were no significant differences in
the distribution of sociodemographic characteristics between car-
riers of Western B and B=; however, there was a trend toward a
higher prevalence ofWestern B strains in the Bang Lamung area of
Chon Buri Province that borders on Pattaya (5/9 for Western B
versus 0/4 for B=, P 0.10), an international tourist destination.
The genetic diversity among RV148 Western B strains (me-
dian, 0.11; interquartile range [IQR], 0.105 to 0.116) was only
slightly higher than the genetic diversity between RV148 and con-
temporaneous reference Western B strains (median, 0.107; IQR,
0.102 to 0.112; P 0.0001) or among contemporaneous reference
Western B strains (median, 0.103; IQR, 0.097 to 0.109; P 
0.0001) (Fig. 2b). Overall, these results support the hypothesis of
multiple introductions of Western B strains in the area. The ge-
netic diversity observed among RV148 B= strains (median, 0.069;
IQR, 0.068 to 0.070; data not shown) was significantly lower than
the one observed among Western B RV148 strains (P 0.001).
Among the Western B strains, there was a pair of sequences
(05TH356764 and 05TH356883) that showed a high level of se-
FIG 2 Location of RV148 subtype B strains in the global subtype B phylogeny. (a) Black circles depict RV148 B strains from theWestern B radiation, and hollow
circles depict RV148 strains from the B= radiation. (b) Distribution of pairwise genetic distance within the cosmopolitan Western B epidemic (blue circles),
among RV148 sequences from theWestern B radiation (green circles), and between these two groups (red circles). This analysis was based on near-full-genome
sequences from344 cosmopolitanWestern B strains that were sampled between 2000 and 2007. (c)Detail of a trio of RV148 strainswith low genetic diversity (red
boxes). (d) Subtree of the B= radiation, where the RV148 strains are highlighted (red boxes). The phylogenetic trees were built using near-full-genome sequences.
Numbers on the branches of the phylogenetic trees represent the percentage of bootstrap replicates supporting the relevant clusters.
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quence identity (distance, 0.021) (Fig. 2c). They were both sam-
pled in the same site 2weeks apart. Neither the remainingWestern
B RV148 strains nor the four strains from the B= radiation showed
a high level of sequence identity to other strains from the same
cohort or to reference strains (Fig. 2d).
(ii) CRF01_AE. CRF01_AE sequences from 12 individuals
were analyzed, including the 6 pure CRF01_AE strains depicted in
Fig. 1 and 6 randomly selected specimens (Fig. 3a). The median
genetic distance among these sequences was 0.068 (IQR, 0.065 to
0.073). The genetic diversity amongCRF01_AERV148 strainswas
significantly higher than the genetic diversity in Thailand from
1990 to 1999 (median, 0.052; IQR, 0.049 to 0.056; P 0.0001) and
2000 to 2004 (median, 0.055; IQR, 0.053 to 0.058; P  0.0001),
indicating that the Thai CRF01_AE epidemic has undergone a
significant expansion in the past 2 decades (Fig. 3b); no contem-
poraneous reference full-genome CRF01_AE sequences from
Thailand were available for comparison. None of the sequenced
RV148 strains showed high similarity with either reference or
other RV148 sequences. Overall, the RV148 sequences were dis-
tributed throughout the East and Southeast Asian CRF01_AE ra-
diation, intermingling with the sequences sampled throughout
the region.
(iii) B/CRF01_AE recombinants. In RV148, by combining
MHAbce and sequencing, we were able to identify 16 recombi-
nants, all of them between subtype B and CRF01_AE; near-full-
genome sequences were generated for 15 of them (Fig. 1).
CRF01_AE comprised the majority of the genomic content of the
RV148 intersubtype recombinants (Fig. 4); 13/15 sequences had a
CRF01_AE genomic content greater than 50% (range, 59.0% to
98.8%). Some genomic areas were CRF01_AE in all of the recom-
binants (e.g., vif and vpu), while in other genomic areas (e.g.,
gp120 in env) there were equivalent numbers of strains carrying
either clade. In 14/15 recombinants, the subtype B components
belonged to the B= radiation. Strain 04TH322500 was the only
intersubtype recombinant whose subtype B content was contrib-
uted by theWestern B radiation (data not shown). The number of
breakpoints observed among RV148 B/CRF01_AE recombinants
did not differ significantly from the number observed among pre-
viously described B/CRF01_AE recombinants (data not shown).
The genomic structures of intersubtype recombinants isolated
in RV148 were compared to those of recombinants containing
subtypes B andCRF01_AE from the published literature. All of the
RV148 recombinants, with the exception of strain 04TH801743,
shared at least one breakpoint with previously reported CRFs and
URFs. Strain 04TH409819 was the only B/CRF01_AE recombi-
nant that shared a full pattern of recombination breakpoints with
a previously described CRF, CRF15_01B, which has been found in
Thailand in individuals attending antenatal/family planning clin-
ics in Lampang and Rayong Provinces (32, 40), an IDU attending
an opiate treatment clinic in Chiang Mai (59), and a female com-
mercial sex worker (CSW) in Bangkok (59) (Fig. 5). There was a
group of six additional strains (i.e., 04TH228266, 05TH245651,
04TH423323, 04TH443479, 05TH522586, and 05TH637314) that
shared both of the CRF15_01B recombination breakpoints in the
envelope region; all of these recombinants incorporated addi-
tional breakpoints in other genomic areas.
FIG 3 Genetic diversity of near-full-genome CRF01_AE sequences in RV148. (a) Location of CRF01_AE RV148 strains in the context of the Asian CRF01_AE
radiation. The different symbols depict the country of sampling of each sequence, as indicated in the box. Sequences sampled in the United States, but likely
acquired in Southeast Asia (85), were also included.Numbers on the branches of the phylogenetic tree represent the percentage of bootstrap replicates supporting
the relevant clusters. (b) Distribution of pairwise nucleotide genetic distances amongCRF01_AE strains in different time periods in the history of the ThaiHIV-1
epidemic: 1990 to 1999 (n 30) and 2000 to 2004 (n 32).
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There were two pairs of B/CRF01_AE recombinants that
shared their complete recombination patterns. Strains
05TH522586 and 05TH637314 were mostly CRF01_AE and con-
tained two subtype B segments in env (Fig. 1). These two segments
corresponded, respectively, to the gp120 segment present in
CRF15_01B and the gp41/second exon of the rev segment present
inCRF34_01B. The genetic distance between these two strainswas
0.039. The volunteers from whom these strains were recovered
were screened at different sites located 12 km apart in Rayong
Province, and their visits occurred 6months apart. The other pair
of strains sharing their complete recombination pattern was
03TH700065and 03TH700078, which were composed of a single
109-bp subtype B fragment in nef embedded in aCRF01_AEback-
ground. The genetic distance between these two strains was 0.026.
This recombinant structure was fully shared with strain
02TH.OUR840I, which had been retrieved from a 2002 incident
infection within an IDU cohort in ChiangMai, Thailand (28); the
genetic distances from 02TH.OUR840I to 03TH700065 and
03TH700078 were 0.055 and 0.058, respectively. Individuals
03TH700065and 03TH700078 were screened on the same day at
the same site in Rayong Province, and the possibility of a direct
epidemiological linkage between them cannot be excluded. For
this reason, and despite the shared recombination pattern with
02TH.OUR840I, this recombinant should not be designated a
CRF at this time.
LocationofRV148 intersubtype recombinants in the context
of the East and Southeast Asian HIV-1 recombinant network.
The irreversible nature of HIV-1 recombination makes recombi-
nation breakpoints extremely useful markers in molecular epide-
miology studies; recombinants are generated within multiply in-
fected individuals, and when transmitted to new individuals, their
genomic structure is preserved as a stable form. Additionally,
transmitted recombinants may further recombine with other
strains in subsequent multiply infected individuals, and some of
the breakpoints from the parental strains may be preserved. We
have previously shown that if shared recombination breakpoints
are used to compare different sequences and strains that share
common recombination breakpoints are grouped together, the
vast majority of the recombinants sampled in East and Southeast
Asia are part of a single, structured, and intricate network (55).
Here we analyzed the RV148 recombinants in the backdrop of the
network composed of all the reported recombinants containing
subtypes B andCRF01_AE (Fig. 6). RV148 strains were an integral
part of the larger East/Southeast Asian network. With the excep-
tion of strain 04TH801743, all of the RV148 strains were linked to
at least one reported strain. RV148 recombinants were directly
linked to reported recombinants sampled in diverse countries
(i.e., Malaysia, Myanmar, Singapore, and Thailand) and from in-
dividuals with diverse reported risk factors for HIV-1 infection
(i.e., IDU and sexual contact). While there were clear connections
FIG 4 CRF01_AE comprises themajority of the genomic content of B/CRF01_AE recombinants in RV148. On the basis of recombination breakpoint mapping,
the subtype composition of all the recombinants was added at each genomic position. Some areas showed equivalent contributions fromCRF01_AE and subtype
B (e.g., gp120 in env), while other areas were predominantly CRF01_AE (e.g., vif).
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linking RV148 strains to other strains from the same cohort,
RV148 strains showed a higher level of connection to reference
strains (P 0.001; data not shown).
HIV-1 subtype distribution and its associationwith sociode-
mographic variables. In East Africa and Thailand, it has previ-
ously been reported that sociodemographic characteristics can be
associated with more genetically complex HIV-1 epidemics (60–
66). In the current study, we explored the association between
recorded sociodemographic variables and the infecting HIV-1
strain. There were no statistically significant differences in the dis-
tribution of subtypes and recombinants on the basis of sex, gen-
der, age, birthplace, marital status, education level, or occupation
(Table 3).
Genetic distance of RV148 strains to immunogens from
RV144 regimen. The cocirculation in Thailand of subtype B,
CRF01_AE, and their recombinants poses an added level of diffi-
culty to the process of HIV-1 vaccine development, and the incor-
poration of subtype B and CRF01_AE immunogens into vaccine
candidates was implemented early on (reviewed in reference 67).
However, genetic changes in the local epidemic occurring in the
time span elapsing from immunogen selection to vaccine testing
might have had profound implications for the success of vaccine
trials and need to be considered in the analysis of vaccine efficacy.
Here we assessed the genetic distance of the RV148 protein se-
quences to the different immunogens, andwe analyze these results
in the context of the evolving HIV-1 epidemics in East and South-
east Asia (Fig. 7).
(i)Distance toCRF01_AEEnv immunogens: 92TH023gp120
linked toLAIgp41 (ALVAC-HIV) andCM244gp120 (AIDSVAX
B/E). Figures 7a and b depict the genetic distance of 21 RV148
strains—13 CRF01_AE B and 8 B/CRF01_AE recombinants
whose corresponding genomic region is CRF01_AE—along with
those of 284 CRF01_AE reference sequences sampled in Thailand,
China, and Vietnam between 1990 and 2009 to the CRF01_AE
Env immunogens. The median distances of RV148 strains to the
CRF01_AE ALVAC-HIV and AIDSVAX B/E Env immunogens
were 0.136 (IQR, 0.127 to 0.145) and 0.155 (IQR, 0.142 to 0.163),
respectively. Interestingly, when analyzing sequences sampled in
Thailand from 1990 to date, there is a clear, progressive, and sig-
nificant increase in the distance to both CRF01_AE Env immuno-
gens: the median distances of sequences from 1990 to 1994 to
ALVAC-HIV and AIDSVAXB/E were 0.081 (IQR, 0.071 to 0.108)
and 0.102 (IQR, 0.081 to 0.120), respectively (see Fig. S1a and b in
the supplemental material). These represent significant increases
in the distance to immunogens of 68% and 52% (P  0.0001),
respectively. Sequences sampled in Thailand and Vietnam be-
tween 1995 and 1999 fit in this progression, and those sampled in
Thailand between 2005 and 2009 were farther away from the im-
munogens than the RV148 samples (median distance to ALVAC-
HIV, 0.146 [IQR, 0.138 to 0.158; P  0.01]; median distance to
AIDSVAX B/E Env, 0.166 [IQR, 0.152 to 0.179; P 0.03]).
(ii) Distance to gp120MN (AIDSVAX B/E). Figure 7c depicts
the genetic distance of 20 RV148 strains—13 subtype B and 7
B/CRF01_AE recombinants whose corresponding genomic re-
gion is subtype B—along with those of 128 subtype B reference
sequences sampled in Thailand, China, Japan, and South Korea
between 1986 and 2009 to the subtype B Env immunogen. The
median distance of RV148 strains to the MN immunogen in
AIDSVAXB/Ewas 0.220 (IQR, 0.201 to 0.239). This reflected only
a 12% increase from the measurement evidenced on sequences
sampled in Thailand from 1990 to 2002 (median, 0.196; IQR,
0.186 to 0.203; P  0.0002) (see Fig. S1c in the supplemental
FIG 5 Seven RV148 B/CRF01_AE intersubtype recombinants share common recombination breakpoints with CRF15_01B and with other published Southeast
Asian recombinants. The vertical dashed lines indicate the location of CRF15_01B breakpoints in the HXB2 coordinate system. See the text for details.
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material); too few reference sequences were available to conduct a
comparison with shorter temporal intervals. Themedian distance
from sequences from China, Japan, and South Korea to the im-
munogen fell within the same range as the RV148 measurement
(0.204, 0.218, and 0.221, respectively).
(iii) Distance to HIV-1 Gag and Pro of LAI (ALVAC-HIV).
Figure 7d depicts the genetic distance of 15 RV148 strains—13
subtype B and 2 B/CRF01_AE recombinants whose correspond-
ing genomic region is subtype B—along with those of 140 subtype
B reference sequences sampled in Thailand, China, Japan, and
South Korea between 1986 and 2009 to the subtype B Gag/Pro
immunogen. The median distance of RV148 strains to LAI was
0.084 (IQR, 0.066 to 0.088), which is 29%greater than the distance
from sequences retrieved in Thailand from 1990 to 2002 (median,
0.065; IQR, 0.060 to 0.074; P  0.0005) (see Fig. S1d in the sup-
plemental material). The distance of subtype B strains sampled in
East Asia—most of them contemporaries of RV148 strains—to
the LAI immunogen was equivalent to that of RV148.
Variation in V1 and V2 of HIV-1 Env. Previous studies have
shown that sequence variation in variable regions 1 and 2 (V1V2)
can dramatically impact antibody binding andneutralization (68–
72). Most recently, analyses in RV144 revealed that the level of
binding of IgG antibodies to V1V2 correlated inversely with the
rate of HIV-1 infection (73) and that there was an increased vac-
cine efficacy against viruses with genetic signatures in V2 (42).
Given the importance of this variable region, we compared the
V1V2 sequences fromRV148 and reference isolates to those of the
vaccine inserts. We focused our analysis on CRF01_AE sequences
from Thailand (1990 to 2009) and the corresponding CRF01_AE
immunogens (i.e., 92TH023 presented in ALVAC-HIV and
CM244 presented in AIDSVAX B/E), as this constituted the larg-
est data set. After excluding areas with extensive length variation,
there were 18 positions where more than 20% of the RV148 se-
quences presented amino acid residues different from those of
RV144 immunogens (i.e., residues 130, 133, 148, 152, 154, 155,
158, 161, 165, 166, 169, 170, 171, 173, 178, 181, 183, and 192 in the
FIG 6 RV148 recombinants are embedded in the larger network of Southeast AsianHIV-1 recombinants. In the network diagram, eachnode represents a recombinant
color coded by country of sampling and shape coded by risk factor for HIV-1 acquisition (risk factors in RV148 were not recorded and thus are depicted as a separate
category). Lines connecting nodes link strains that share common recombination breakpoints, and they are color coded to help distinguish relationshipswithin RV148,
within published strains, and between these two groups. Boxes group together strains that belong to the same CRF. Numbers within the nodes identify the strains, as
follows: 1, 04TH228466; 2, 05TH245651; 3, 04TH312908; 4, 04TH321566; 5, 04TH322500; 6, 04TH409819; 7, 04TH423323; 8, 05TH443479; 9, 05TH522586; 10,
05TH637314; 11, 03TH700065; 12, 03TH700078; 13, 04TH704320; 14, 04TH801743; 15, 05TH852327; 16, 01B.MM.1999.mCSW104; 17, 01B.MM.2000.mIDU502; 18,
01B.MY.2003.03MYKL018_1; 19, 01B.MY.2004.04MYKL016_1; 20, 01B.MY.2004.04MYKL019_1; 21, 01B.MY.2005.05MYKL043_1; 22, 01B.MY.2006.06MMYKLD46; 23,
01B.MY.2007.07MYKLD47; 24, 01B.MY.2007.07MYKLD48; 25, 01B.MY.2007.07MYKLD49; 26, 01B.TH.-0.1269 12_69; 27, 01B.TH.-.CM237; 28, 01B.TH.-.CU98_26;
29, 01B.TH.-.MU2003; 30, 01B.TH.-.NP1623; 31, 01B.TH.-.TH1326; 32, 01B.TH.-.TH283; 33, 01B.TH.-.TH9_95; 34, 01B.TH.1996.M005; 35, 01B.TH.1996.M043; 36,
01B.TH.1996.M171;37,01B.TH.1999.OUR2574;38,01B.TH.2000.00TH_C2254_BE;39,01B.TH.2000.00TH_R1741;40,01B.TH.2001.OUR033I;41,01B.TH.2002.OUR740I;
42, 01B.TH.2002.OUR840I; 43, 01B.TH.2002.OUR846I; 44, 01B.TH.2002.OUR847I; 45, 01B.US.1998.99US_MSC5043; 46, 01BC.MM.1999.mIDU107; 47,
01BC.MM.2000.mCSW503;48,15_01B.TH.1996.M169;49,15_01B.TH.1999.99TH_MU2079;50,15_01B.TH.1999.99TH_R2399;51,15_01B.TH.2002.02TH_OUR1331;52,
15_01B.TH.2002.02TH_OUR1332; 53, 33_01B.MY.05.05MYKL045_1; 54, 33_01B.MY.2005.05MYKL007_1; 55, 33_01B.MY.2005.05MYKL015_2; 56,
33_01B.MY.2005.05MYKL031_1; 57, 34_01B.TH.1999.OUR1969P; 58, 34_01B.TH.1999.OUR2275P; 59, 34_01B.TH.1999.OUR2478P; 60, 48_01B.MY.2007.07MYKT014;
61, 48_01B.MY.2007.07MYKT016; 62, 48_01B.MY.2007.07MYKT021; 63, 51_01B.SG.2011.11SG_HM021; 64, 51_01B.SG.2011.11SG_HM091. See the text for details.
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HXB2 numbering system). In all of these sites, sequence variation
was not restricted to RV148 but could be evidenced throughout
the 2 decades that spanned molecular epidemiology studies in
Thailand, with no consistent temporal trend (data not shown).
Also, the amino acid residues involved in toggling at each position
coincided among the compared periods, probably reflecting con-
vergent elicitation of immune responses and pathways of viral
escape during natural HIV-1 infection. The sieve analysis con-
ducted on RV144 breakthrough cases revealed significant differ-
ences between vaccine and placebo recipients in the amino acid
residues represented at positions 169 and 181; the vaccine efficacy
was higher against viruses carrying a lysine at position 169 (169K)
and against viruses not carrying an isoleucine at position 181
(181X) (42). Figure 8 shows that, in RV148, 11/21 individuals
TABLE 3 Comparison of sociodemographic variables across the different genotypes detected among 375 HIV-infected volunteers deferred from
enrollment in RV144
Characteristic
No. (%) of volunteers with the following genotype:
Odds ratio for non-
CRF01_AE (95% CI)Total CRF01_AE Subtype B
B/CRF01_AE
recombinants
B/CRF01_AE
dual infection
Sex
Female 183 172 (94.0) 5 (2.7) 6 (3.3) 0 (0.0) Reference
Male 192 172 (89.6) 8 (4.2) 10 (5.2) 2 (1.0) 1.82 (0.85–3.91)
Gender
Female 192 181 (94.3) 5 (2.6) 6 (3.1) 0 (0.0) Reference
Male 182 162 (89.0) 8 (4.4) 10 (5.5) 2 (1.1) 2.03 (0.94–4.4)
Missing 1 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NAa
Age (yr)
18–25 185 170 (91.9) 8 (4.3) 6 (3.2) 1 (0.5) Reference
26–30 190 175 (91.6) 5 (2.6) 10 (5.3) 1 (0.5) 1.04 (0.50–2.17)
Birthplace
Rayong 85 80 (94.1) 1 (1.2) 4 (4.7) 0 (0.0) Reference
Chon Buri 92 82 (89.1) 6 (6.5) 3 (3.3) 1 (1.1) 1.95 (0.66–6.50)
Other 198 182 (91.9) 6 (3.0) 9 (4.6) 1 (0.5) 1.40 (0.53–4.42)
Marital status
Single 112 103 (92.0) 4 (3.6) 4 (3.6) 1 (0.9) Reference
Married 206 187 (90.8) 7 (3.4) 11 (5.3) 1 (0.5) 1.16 (0.52–2.78)
Separated 2 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Divorced 49 46 (93.9) 2 (4.1) 1 (2.0) 0 (0.0) 0.75 (0.16–2.63)
Widowed 6 6 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Education
Primary 196 177 (90.3) 7 (3.6) 11 (5.6) 1 (0.5) Reference
Did not complete primary
school
17 15 (88.2) 1 (5.9) 1 (5.9) 0 (0.0) 1.24 (0.19–4.87)
Junior high school 111 103 (92.8) 5 (4.5) 2 (1.8) 1 (0.9) 0.72 (0.29–1.66)
Senior high school/vocational
school
41 39 (95.1) 0 (0.0) 2 (4.9) 0 (0.0) 0.48 (0.07–1.74)
Vocational school 7 7 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Bachelor’s degree or higher 3 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Occupation
Office/factory 87 80 (92.0) 1 (1.1) 5 (5.8) 1 (1.1) Reference
Laborer 117 108 (92.3) 2 (1.7) 6 (5.1) 1 (0.9) 0.95 (0.34–2.77)
Merchant/business 31 30 (96.8) 1 (3.2) 0 (0.0) 0 (0.0) 0.38 (0.02–2.27)
Housewife 24 24 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Entertainment 20 19 (95.0) 1 (5.0) 0 (0.0) 0 (0.0) 0.60 (0.03–3.68)
Agriculture 16 14 (87.5) 1 (6.3) 1 (6.3) 0 (0.0) 1.63 (0.23–7.63)
Male/female CSW 15 13 (86.7) 1 (6.7) 1 (6.7) 0 (0.0) 1.76 (0.24–8.28)
Fishery 8 7 (87.5) 1 (12.5) 0 (0.0) 0 (0.0) 1.63 (0.08–11.3)
Government officer 5 5 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Military/police 4 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0) 3.81 (0.18–34.7)
Student 3 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Other 2 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
Unemployed 43 36 (83.7) 4 (9.3) 3 (7.0) 0 (0.0) 2.22 (0.71–6.95)
a NA, not applicable.
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carried 169K, which was less than the proportion evidenced
among viruses sampled inThailand from1995 to 1999 and 2000 to
2004 (unadjusted P  0.07 and 0.053, respectively). Similarly,
9/21 individuals carried the 181X signature in RV148, which rep-
resented a proportion greater than the proportions evidenced
from 1990 to 1995, 2000 to 2004, and 2005 to 2009 (unadjusted
P 0.02, 0.04, and 0.07, respectively). Due to the large numbers of
comparisons carried out, these unadjusted P values should be in-
terpreted as trends.
V1V2 is notable for its high level of N-glycosylation; RV148
sequences presented a median of 8 potential N-glycosylated sites
(IQR, 7 to 10), which did not differ significantly from that for
reference sequences (data not shown). Despite V1V2 sequence
variation, the N-glycosylation site 160 and the cationic nature of
the C strand, which have been shown to be critical for neutraliza-
tion by PG9 and related antibodies, were conserved amongRV148
and reference sequences (data not shown). Overall, this analysis
shows that there have been no notable changes in the patterns of
V1V2 sequence variation amongCRF01_AE strains in Thailand in
the past 2 decades.
DISCUSSION
RV144 was the first vaccine trial to demonstrate a significant,
thoughmodest, protection fromHIV-1 acquisition (modified in-
tent-to-treat vaccine efficacy, 31.2% [95%CI, 1.1 to 52.1%]) (56).
Subsequent studies have defined correlates of risk, importantly,
vaccine-induced IgG to the V1V2 region (73), and analysis of
breakthrough infections (42) has further identified genetic signa-
tures in Env, particularly at HXB2 amino acid positions 169 and
181, which are associated with vaccine efficacy. In the broader
context, understanding themolecular epidemiology of volunteers
deferred from enrollment in RV144 due to preexisting HIV-1 in-
fection (i) provides a cross-sectional representation of the HIV-1
epidemic in Thailand at the time of recruitment for RV144, (ii)
helps better define who volunteered for the trial, and (iii) is an
important approximation to the viral strains that challenged the
vaccine and placebo recipients in RV144 and their relationship to
the immunogens.
Cross-sectional representation of theHIV epidemic in Thai-
land at the time of recruitment for RV144. In RV148, we ob-
served that the predominant strain, with a prevalence of over 90%,
FIG 7 Temporal and geographical differences in the distance of southeast Asian strains to RV144 immunogens. (a) Protein distance of RV148 CRF01_AE and
B/CRF01_AE recombinantswhose gp120 region isCRF01_AE andpublishedHIV-1CRF01_AE strains sampled in East and Southeast Asia to the 92TH023 gp120
linked to the LAI gp41 immunogen presented in the ALVAC-HIV. (b) Protein distance of RV148 CRF01_AE and B/CRF01_AE recombinants whose gp120
region is CRF01_AE and published HIV-1 CRF01_AE strains sampled in East and Southeast Asia to the CM244 gp120 immunogen presented in the AIDSVAX
B/E. (c) Protein distance of RV148 subtype B and B/CRF01_AE recombinants whose gp120 region is subtype B and published HIV-1 subtype B strains sampled
in East and Southeast Asia to the MN gp120 immunogen presented in the AIDSVAX B/E. (d) Protein distance of RV148 strains to subtype B and B/CRF01_AE
recombinants whose gag-pro region is subtype B and publishedHIV-1 subtype B strains sampled in East and Southeast Asia to the LAIGag immunogen presented
in the ALVAC-HIV. Each point in the radar chart depicts an RV148 (hollow circles) or published strain (full circle), and its radial distance to the center represents
the protein p-distance to the immunogen. Concentric circles show the distance scale. The country and year of sampling are indicated.
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was CRF01_AE, followed by equivalent proportions of subtype B
and B/CRF01_AE recombinants and only minor occurrences of
dual infections. These results are in high concordance with the
findings of the community cohort studies performed in the same
area between 1998 and 2001 in preparation for RV144 (40). Re-
garding the level of genetic diversity among full-genome
CRF01_AE sequences in RV148, we noticed increases of 31% and
24% compared to the measurements from Thailand from 1990 to
1999 and 2000 to 2004, respectively. This observation supports
previous observations indicating that in the past 2 decades the
CRF01_AE Thai epidemic has experienced a continued genetic
expansion (25).
The proportion of RV148 strains that were subtype B was
3.5%. An interesting aspect of the East and Southeast AsianHIV-1
epidemics is the cocirculation of two different clusters within sub-
type B: Western B and B= (57, 58). The latter is widespread
throughout the region and has been incorporated by the vast ma-
jority of subtype B-containing recombinants (e.g., CRF07_BC,
CRF08_BC, and CRF15_01B). In RV148, the Western B strains
outnumbered the B= strains in a 2:1 ratio. Our phylogenetic anal-
yses indicate that the Western B strains did not proceed from a
single source but seemed to be part of the larger, cosmopolitan,
and contemporary Western B epidemic. The fact that more than
half of theWestern B strains in RV148 were sampled near Pattaya,
a hub for international tourism, suggests that this area may be an
important port of entry for these strains.While B= strains continue
to be detected in Thailand, they do not seem to constitute the
majority of the subtype B strains in Rayong and Chon Buri Prov-
inces. It is possible that the populations that used to bear B= strains
were high-risk groups (e.g., IDUs) and became superinfected with
CRF01_AE strains, which led to the emergence of numerous
B/CRF01_AE URFs (28). It can be expected that if the process of
absorption of B= strains into B/CRF01_AE recombinants persists
and the influx ofWestern B strains continues, pure B= strains may
eventually be replaced by Western B strains in the Thai HIV-1
epidemic. In contrast to the evolution of B=, the incorporation of
Western B strains in B/CRF01_AE recombinants has been re-
stricted to a few examples (e.g., CRF51_01B [74], CM237 [75],
and strain 04TH322500 in the current study), which suggests that
Western B circulates in social networks where dual infection and
dissemination of recombinants is not frequent.
The cocirculation of subtype B and CRF01_AE in Southeast
Asia has led to the emergence of intersubtype recombinants.
While some of them expanded in the population (e.g.,
CRF15_01B and CRF34_01B) (59, 76), the majority of recombi-
nants have been sampled only on single occasions (i.e., URFs). An
interesting feature of the URFs in Thailand is that most of them
share common recombination breakpoints. Molecular epidemio-
logical studies support the hypothesis that these similarities reflect
common ancestry (28, 77–79), though some common break-
points may represent independent and convergent events (80). In
RV148, 1 out of 15 sequenced B/CRF01_AE recombinants be-
longed to a CRF, CRF15_01B, which is the CRF that has spread
among different provinces and social networks throughout Thai-
FIG 8 Amino acid variation in V1V2 positions 169 and 181 among CRF01_AE sequences sampled in Thailand between 1990 and 2009 and their relation to the
RV144 vaccine immunogens. The frequency of each amino acid residue at the corresponding position is depicted for published Thai CRF01_AE gp120 sequences
sampled between 1990 and 1994 (n 20), 1995 and 1999 (n 36), 2000 and 2004 (n 35), and 2005 and 2009 (n 71), as well as CRF01_AE and B/CRF01_AE
recombinants whose gp120 region is CRF01_AE from RV148 (n  21). The amino acid residues presented in 92TH023 and CM244 RV144 immunogens are
depicted for comparison.
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land (32, 59). Additionally, 6 URFs shared with CRF15_01B both
of the signature recombination breakpoints in env, suggesting that
this CRF plays a central role in the Thai HIV-1 epidemic, not only
by spreading to some extent as a stable form but also as a major
contributor of genetic material to new recombinants. The
genomic structure of CRF15_01B can be compared to a pseu-
dotype virion (81), as it is composed of a single B= segment ex-
tending from the beginning of gp120 (excluding the leader pep-
tide, which is CRF01_AE) to the end of the ectodomain of gp41 in
a CRF01_AE background. The retention of these motifs in the
CRF15_01B-derived URFs reiterates a phenomenon observed in
other subtype B-containing recombinants sampled worldwide
(e.g., CRF14_BG [82]) andmay indicate that thesemotifs interact
better in this configuration, which warrants further structural and
functional analyses (A.-L. Chenine et al., unpublished data).
It has previously been shown that the sharing of recombination
breakpoints among CRFs and URFs in East and Southeast Asia
links virtually all of these recombinants in a single network, which
connects strains from different geographic locations and strains
sampled from individuals with different routes for HIV-1 acqui-
sition (55). Here we have shown that all but one of the RV148
recombinants are fully integrated within this larger network. The
fact that the direct connectedness of RV148 to other reference
recombinants was higher than the direct connectedness to other
members of RV148 indicates that recombinants in RV148 did not
proceed from a single pocket or subpopulation but, rather, that
they represent a more diverse pool of sequences. This may shed
light on the social networks from which the RV148 volunteers
were drawn (see below).
Who volunteered for the trial? The information retrieved
from RV148 volunteers included basic sociodemographic charac-
teristics, but the volunteers were not asked questions regarding
behaviors that may increase the risk for HIV acquisition (41). In
cohorts in Thailand and worldwide, it has been shown that there
were associations between the complexity of HIV-1 strains and
sociodemographic characteristics and behaviors thatmay increase
the risk of HIV infection (e.g., more frequent needle sharing
among IDUs [61], the presence of sexually transmitted infections
[63], exchanging sex formoney [65, 66), andhaving high numbers
of sex partners [66]). We compared the frequency of different
molecular forms—pure subtypes and recombinants—between
RV148 and other low-risk cohorts (i.e., RV109, a mother-to-child
transmission [MTCT] study conducted in Lampang between
1996 and 1997 [32]) and high-risk cohorts (i.e., a study conducted
among IDUs seeking treatment in Chiang Mai between 1999 and
2000 [61] and the Thai Red Cross [TRC] study conducted among
high-risk men who have sex with men [MSM] and heterosexuals
in Bangkok between 2006 and 2007 [83]) fromThailand that have
also been genotyped using MHAbce. In RV148, the frequency of
non-CRF01_AE strains (9.8%) was higher than that in the low-
risk MTCT study (5.1%) but lower than the ones observed in
higher-risk cohorts: IDUs (18.7%) and high-risk MSM and het-
erosexuals (20%). In RV148, the combined frequency of complex
molecular forms (i.e., recombinants and dual infections) was
6.6%; likewise, these complex strains were more frequent in
RV148 than in the low-riskMTCT cohort (2.3%) but less frequent
in RV148 than in the high-risk Opiate-Users Research (14.7%)
and TRC (13%) cohorts. Overall, these results are consistent with
the idea that the level of risk for HIV-1 infection among RV148
HIV-infected individuals was at the level of what is expected from
a community-based cohort, which was the aim of RV144 (56).
While individuals belonging to groups with high-risk behaviors
may also have volunteered for the trial, their representation in
RV148 seems to be only minor. This is an important point, as the
level of risk of vaccine trial populations can impact the observed
vaccine efficacy (84).
The fact that in RV148 we observed a large number of URFs
along with a limited number of multiply infected individuals can
be explained through the model through which, in the region,
there are small groups with high levels of exposure to HIV-1,
where recombinants are being generated in multiply infected in-
dividuals. The linkage of these groups with the larger, lower-risk
community then leads to the dissemination of URFs. Following
this model, in order to limit the expansion in HIV-1 genetic di-
versity, public health efforts should be directed at identifying these
high-risk groups and strengthening effective intervention cam-
paigns.
An approximation to the viral strains that challenged the
vaccine and placebo recipients in RV144 and their relationship
to the immunogens. The complex activities involving vaccine de-
velopment can take more than a decade from the time of im-
munogen selection until testing in efficacy trials. Even if the im-
munogens were chosen to minimize the mismatch to the
circulating strains at the time of vaccine development, the molec-
ular characteristics of the local epidemic can dramatically change
by the time of vaccine testing in efficacy trials. Here we showed
that the distance to the immunogens increased 52% to 68% for
CRF01_AE Env, 12% for subtype B Env, and 29% for subtype B
Gag-Pro from the early 1990s to the mid-2000s. The CRF01_AE
Thai epidemic in the early 1990s was very compact and continued
expanding throughout the decade. Considering the data for the
period from 2005 to 2009 from Thailand, the increase in genetic
diversity had not plateaued at the time of RV148. On the other
hand, it seems that the subtype B epidemic is not expanding at
such a fast pace. It is important to continue the molecular charac-
terization of communities where vaccine trials are planned, as this
phenomenon can impact the analysis of vaccine efficacy in future
trials. At the time of RV148, the distance of CRF01_AE and sub-
type B strains from other countries in East and Southeast Asia to
the immunogens was equivalent to that measured in Thailand.
This means that the distance of circulating HIV-1 strains to the
immunogen should not be a major concern at the time of extend-
ing the testing/usage of the RV144 vaccine regimen to other coun-
tries in the region.
Of note, the above-mentioned protein distance calculations
were based on the entirety of the immunogen sequence. The anal-
ysis of immunological correlates of protection from acquisition in
RV144 has revealed a significant inverse association between
binding of IgG antibodies to V1V2 and infection risk (73). This
region of gp120 is recognized as one of the most variable areas of
the HIV-1 proteome. Our analysis of CRF01_AE strains indicates
that the nature and level of sequence variation in highly polymor-
phic sites in V1V2 have been maintained since the early 1990s to
date, in contrast to the results from the analyses based on the
whole immunogen. Some V1V2 sites showed an extremely high
level of mismatch between RV148 sequences and immunogens;
48% and 43% of the sequences differed from the sequence of the
vaccine insert in positions 169 and 181, respectively, with some
trends suggesting differences with previous time points. Interest-
ingly, these are two sites where recent analyses by Rolland et al.
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have detected significant sieve effects in RV144 (42), further sup-
porting the need for continuing molecular epidemiological sur-
veys in communities where vaccine efficacy trials are planned or
under way.
Limitations of the study. The current study, involving nearly
400 individuals, constitutes one of the largest HIV-1 molecular
surveys conducted in Southeast Asia to date; however, it has sev-
eral limitations. The use of high-throughputMHAbce allowed the
cost-effective genotyping of virtually the entire cohort and al-
lowed the detection of recombinants that would have beenmissed
by partial-genome sequencing; nevertheless, it is possible that
some of the samples typed as pure CRF01_AE may in fact be
recombinants incorporating other subtypes in genomic areas not
interrogated byMHAbce. Additionally,MHAbce is not capable of
detecting multiple infections due to the same clade (e.g., coinfec-
tionwith two distinct CRF01_AE strains). Thus, the current tallies
of recombinants and multiple infections should be considered
lower-limit estimates. Another limitation of the current study
arises from the fact that near-full-genome sequences were re-
trieved fromonly 10%of the individuals, with special emphasis on
subtype B and intersubtype recombinants. For this reason, the
study was not powered to systematically address the presence of
direct epidemiological linkage amongHIV-1 infected individuals,
especially among those infected with CRF01_AE.
Finally, the current work focused exclusively on the RV144
volunteers deferred from enrollment in the vaccine trial due to
preexisting HIV-1 infection. The thorough analysis of RV144
breakthrough cases is the focus of a separate report (Rolland, per-
sonal communication) and will provide wider context to the cur-
rent observations.
Conclusion. In summary, our results show that at the time of
enrollment for RV144, the HIV-1 epidemic in Rayong and Chon
Buri Provinces was dominated by CRF01_AE strains. Some rep-
resentation of subtype B was noted, with an increase in the West-
ern B frequency due to multiple entries in the region and waning
of B= being detected. Most of the intersubtype recombinants were
URFs embedded within the larger regional network of recombi-
nants. The level of genetic complexity observed in this study
strongly indicates that the RV148 volunteers presented risk levels
consistent with those for a community-based cohort. Compared
to themolecular picture at the early stages of the process of vaccine
development, we evidenced substantial changes in the epidemic
(i.e., the expansion of the genetic diversity within CRF01_AE, the
increase in the frequency and complexity of B/CRF01_AE recom-
binants, and shifts in the Western B/B= balance) which had the
potential to impact the efficacy of the vaccine and should be con-
sidered at the time of the analysis of the trial results.
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Figure S1. Temporal and geographical differences in the distance of southeast Asian 
strains to RV144 immunogens. a) Protein distance of RV148 CRF01_AE and 
B/CRF01_AE recombinants whose gp120 region is CRF01_AE, and published HIV-1 
CRF01_AE strains sampled in East and Southeast Asia, to the 92TH023 Gp120 linked to 
LAI gp41 immunogen presented in the ALVAC-HIV. b) Protein distance of RV148 
CRF01_AE and B/CRF01_AE recombinants whose gp120 region is CRF01_AE, and 
published HIV-1 CRF01_AE strains sampled in East and Southeast Asia, to the CM244 
Gp120 immunogen presented in the AIDSVAX B/E. c) Protein distance of RV148 
subtype B and B/CRF01_AE recombinants whose gp120 region is subtype B, and 
published HIV-1 subtype B strains sampled in East and Southeast Asia, to the MN Gp120 
immunogen presented in the AIDSVAX B/E. d) Protein distance of RV148 strains to 
subtype B and B/CRF01_AE recombinants whose gag-pro region is subtype B, and 
published HIV-1 subtype B strains sampled in East and Southeast Asia, to the LAI Gag 
immunogen presented in the ALVAC-HIV. Each point in the charts depicts an RV148 
(hollow circles) or published strain (full circle). The country and year of sampling are 
indicated. 
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